secwatch / observer
8-K filed June 11, 2024, 7:59 PM ET CIK 0001654151
M&A confidence high sentiment neutral materiality 0.90

Deciphera Pharmaceuticals, Inc.: M&A transaction — Ono completes $2.4B acquisition of Deciphera; shares converted at $25.60 each

Deciphera Pharmaceuticals, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Toichi Takino

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Filed
June 11, 2024, 7:59 PM ET
Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors
Departed

Dennis L. Walsh

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed

James A. Bristol

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed

Ron Squarer

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed

Frank S. Friedman

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed

Patricia L. Allen

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed

Susan L. Kelley

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed

Edward J. Benz, Jr.

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Appointed

Masayuki Tanigawa

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Filed
June 11, 2024, 7:59 PM ET
Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors
Departed

John R. Martin

Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Toichi Takino was appointed as Director at Deciphera Pharmaceuticals, Inc..

Action
appointed
Role
Director
Exact text from the filing
Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dennis L. Walsh resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

James A. Bristol resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ron Squarer resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Frank S. Friedman resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Patricia L. Allen resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Susan L. Kelley resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Edward J. Benz, Jr. resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Masayuki Tanigawa was appointed as Director at Deciphera Pharmaceuticals, Inc..

Action
appointed
Role
Director
Exact text from the filing
Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John R. Martin resigned as Director at Deciphera Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Deciphera Pharmaceuticals, Inc. underwent a change of control involving Ono Pharmaceutical Co., Ltd. for $25.60 per share in cash (closed 2024-06-11).

Action
change of control
Counterparty
Ono Pharmaceutical Co., Ltd.
Consideration
$25.60 per share in cash
Closing
2024-06-11
Exact text from the filing
May 13, 2024 to acquire all of the issued and outstanding shares of common stock, par value $0.01 per share, of the Company (“ Company Common Stock ”), at a price per share of $25.60, net to the seller in cash, without interest and subject to any withholding of taxes required by applicable law. The Offer and related withdrawal rights expired at one minute
View on SEC.gov

15 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Source: SEC EDGAR
accession 0001193125-24-158772
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.